ICER draft report: Aimmune's peanut allergy therapy cost effective, DBV's falls short

ICER thinks Aimmune's peanut allergy therapy AR101 could be cost effective but found that DBV’s Viaskin Peanut exceeded standard cost-effectiveness ratios, according to a draft evidence report published Tuesday.

The institute said both therapies may provide some benefit for patients relative to avoidance alone, but emphasized the ultimate value is dependent on the therapies' eventual prices. ICER estimated AR101 would result in 0.63 incremental quality-associated life years (QALYs), while Viaskin Peanut would result in 0.22 incremental QALYs, compared with avoidance alone...